Table 1.
Presence or absence of cervical arterial calcification in quartiles based on serum osteoprotegerin, osteocalcin, FGF23, and 25-hydroxyvitamin D3 levels in 124 patients with type 2 diabetes
| 1st quartile | 2nd quartile | 3rd quartile | 4th quartile | |
|---|---|---|---|---|
| Serum osteoprotegerin (pg/ml) a |
<5.6 |
5.6-8.4 |
8.5-52.7 |
52.8- 9027 |
| No calcification, n |
26* |
25 |
19 |
16# |
| Calcification, n |
5# |
6 |
12 |
15* |
| Serum osteocalcin (ng/ml) b |
0.77-0.82 |
0.83-0.92 |
0.93-1.53 |
1.60-10.56 |
| No calcification, n |
24 |
18 |
21 |
23 |
| Calcification, n |
7 |
13 |
10 |
8 |
| Serum FGF23 (pg/ml) c |
10.0-22.7 |
22.9-29.0 |
29.7-40.7 |
42.0- 148.0 |
| No calcification, n |
24 |
20 |
19 |
23 |
| Calcification, n |
7 |
11 |
12 |
8 |
| Serum 25-hydroxyvitamin D3 (nmol/l) d |
29.2-48.1 |
48.6-77.3 |
78.6-119.1 |
121.1-239.3 |
| No calcification, n |
20 |
19 |
25 |
22 |
| Calcification, n | 11 | 12 | 6 | 9 |
a P=0.015 by chi-square test. *: Number of subjects significantly greater than other quartiles. #: Number of subjects significantly less than other quartiles.
b P=0.278 by chi-square test.
c P=0.499 by chi-square test.
d P=0.364 by chi-square test.